Skip to main content

Qiagen Value Stock - Dividend - Research Selection

Qiagen

ISIN: NL0012169213, WKN: A2DKCH

Market price date: 03.04.2020
Market price: 40,27 USD




Qiagen Fundamental data and company key figures of the share

Annual reports in USD
Key figures 04-03-2020
Cash flow
Net operating cash flow 330.843.000
Capital Expenditures -274.884.000
Free cash flow 55.959.000
Balance sheet
Total Equity 2.536.590.000
Liabilities & Shareholders equity 5.235.620.000
Income statement
Net income -41.455.000
Eps (diluted) -0,180
Diluted shares outstanding 230.306.000
Net sales/revenue 1.526.420.000

Fundamental ratios calculated on: 03-04-2020

Ratios
Key figures 03-04-2020
Cash flow
P/C 28,03
   
P/FC 165,74
Balance sheet
ROI-0,79
ROE48,45
Income statement
P/E-223,72
Div. Yield0,00%
P/B3,66
P/S6,08


Do you want to do make a detailed fundamental analysis of this stock?

Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolQGEN
Market Capitalization9.274.422.272,00 USD
CountryGermany
IndicesHDAX,MDAX,NASDAQ Comp.,TecDAX
SectorsHealth service
Raw Data SourceUS GAAP in Millionen USD
Stock Split2017-01-26,962.0000/1000.0000; 2017-01-25,962.0000/1000.0000; 2000-07-14,4.0000/1.0000; 1999-07-16,2.0000/1.0000
Internetwww.qiagen.com


Description of the company

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.qiagen.com